Clinical trials: sponsored by Ohio State University Comprehensive Cancer Center
Cervical Abnormality
Community Awareness, Resources and Education (CARE I): Project 3
Community Awareness, Resources and Education (CARE) Project - Project 3 will determine if Appalachian women have unique risk factors for an abnormal Pap smear that might contribute to the increased risk of cervical abnormalities…
- Trial name
- NCT02113514
- Where
- 2 sites in United States
- Volunteers
- 2,394 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Partial-Breast Radiation Therapy in Treating Women With Early-Stage Breast Cancer
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. It may also cause less damage to normal tissue.
- Trial name
- NCT01008514
- Testing
- adjuvant therapy, accelerated partial breast irradiation, intracavitary balloon brachytherapy
- Sponsor
- Ohio State University Comprehensive Cancer Center
Graft Versus Host Disease, Hematopoietic/Lymphoid Cancer
Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease
This research trial studies lymphocyte profiles and activation status in patients with graft-versus-host disease. Studying samples of blood in the laboratory from patients with cancer may help doctors identify and learn more…
- Trial name
- NCT01988701
- Testing
- Ancillary-Correlative
- Sponsor
- Ohio State University Comprehensive Cancer Center
Melanoma
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
The purpose of this study is to determine the safety, tolerability and dose limiting toxicities (DLTs) of VELCADE when administered in combination with interferon-alpha-2b (IFN-α-2b) to patients with metastatic malignant melanoma.
- Trial name
- NCT01462773
- Testing
- Bortezomib, Interferon Alfa-2b
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Cancer
Prostate Biomarkers in Men Consuming Tomato Products
Prostate Biomarkers in Men Consuming Tomato Products
- Trial name
- NCT02292524
- Testing
- Commercially-available tomato food product
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Colon Cancer, Rectal Cancer
Patient Activation Intervention in Improving Screening Rates for Colorectal Cancer
This randomized clinical trial focused on activating the patient to ask their health care provider for a colorectal cancer screening test to improve screening rates for colorectal cancer.
- Trial name
- NCT01801059
- Testing
- educational intervention, questionnaire administration
- Where
- United States
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Cancer
Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy
RATIONALE: Tomato-soy juice may slow the growth of tumor cells. Studying samples of blood and tissue from patients with prostate cancer in the laboratory may help doctors identify biomarkers related to cancer.
- Trial name
- NCT01009736
- Testing
- tomato-soy juice, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lung Cancer, Non-Small-Cell Lung Carcinoma
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients
This study will determine the objective response rate in chemotherapy naive non-small cell lung cancer patients with advanced disease.
- Trial name
- NCT00201825
- Testing
- Capecitabine, Docetaxel
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Tony Bekaii-Saab
Intraocular Pressure
Steep Trendelenburg Positioning on Intra-Ocular Pressure During Surgery for Endometrial Robotics Versus Laparotomy
The purpose of this study is to assess changes of intra-ocular pressure (IOP) and examine preoperative facts affecting IOP in endometrial cancer patients undergoing robotic hysterectomy compared to laparotomy.
- Trial name
- NCT00852774
- Volunteers
- healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer, Depression
Hatha Yoga in Improving Physical Activity, Inflammation, Fatigue, and Distress in Breast Cancer Survivors
RATIONALE: Yoga may improve inflammation, fatigue, and depression in female breast cancer survivors. PURPOSE: This randomized clinical trial is studying how well Hatha yoga works in improving physical activity, inflammation…
- Conditions
- Breast Cancer, Depression, Fatigue, Pain
- Trial name
- NCT00486525
- Testing
- Yoga Therapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer, Weight Loss
Low Fat Versus Protein Sparing Diet for Weight Loss & Impact on Biomarkers Associated With Breast Cancer Risk
The primary specific aim of this study was to determine if overweight and obese premenopausal women can lose weight and if long term weight loss impacts biomarkers associated with breast cancer risk.
- Trial name
- LEAF (NCT01559194)
- Testing
- Low Fat Diet plus exercise, Low Carbohydrate diet + Exercise
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Head and Neck Cancer
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00061906
- Testing
- celecoxib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Leukemia
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005758
- Testing
- cyclophosphamide, cytarabine, dexamethasone
- Volunteers
- 180 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
RATIONALE: Bortezomib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Trial name
- NCT01129180
- Testing
- azacitidine, bortezomib, Correlative studies
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Pierluigi Porcu
Malignant Neoplasm
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
Palonosetron is different from ondansetron because it stays in the body longer and may prevent nausea and vomiting for a longer period of time than ondansetron.
- Trial name
- NCT01640340
- Testing
- aprepitant, palonosetron hydrochloride, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Renal Cancer
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
This study will determine the response rate of daily low dose interferon-alpha-2b in patients with metastatic or unresectable clear cell renal cell carcinoma.
- Trial name
- NCT00293527
- Testing
- Interferon Alpha-2b
- Sponsor
- Ohio State University Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004173
- Testing
- oxaliplatin, paclitaxel
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00009932
- Testing
- cisplatin, fenretinide, paclitaxel
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Leukemia
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as cytarabine, daunorubicin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00124644
- Testing
- cytarabine, daunorubicin hydrochloride, etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic…
- Trial name
- NCT00017199
- Testing
- bortezomib
- Where
- 2 sites in United States
- Sponsor
- Ohio State University Comprehensive Cancer Center